Avenue Therapeutics Inc. [NASDAQ: ATXI] surged by $3.74 during the normal trading session on Tuesday and reaching a high of $11.12 during the day while it closed the day at $7.26. The company report on September 22, 2022 that Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022, and also provided a regulatory update related to its intravenous (“IV”) Tramadol product candidate.
Avenue Therapeutics Inc. stock has also gained 115.69% of its value over the past 7 days. However, ATXI stock has inclined by 97.55% in the 3 months of the year. Over the past six months meanwhile, it has lost -0.21% and lost -46.70% year-on date.
The market cap for ATXI stock reached $15.68 million, with 1.46 million shares outstanding and 0.71 million shares in the current float. Compared to the average trading volume of 243.21K shares, ATXI reached a trading volume of 58412503 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Avenue Therapeutics Inc. [ATXI]:
The Average True Range (ATR) for Avenue Therapeutics Inc. is set at 1.70 The Price to Book ratio for the last quarter was 17.71, with the Price to Cash per share for the same quarter was set at 0.42.
ATXI stock trade performance evaluation
Avenue Therapeutics Inc. [ATXI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 115.69. With this latest performance, ATXI shares gained by 87.09% in over the last four-week period, additionally sinking by -0.21% over the last 6 months – not to mention a drop of -68.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATXI stock in for the last two-week period is set at 62.99, with the RSI for the last a single of trading hit 65.07, and the three-weeks RSI is set at 61.35 for Avenue Therapeutics Inc. [ATXI]. The present Moving Average for the last 50 days of trading for this stock 4.08, while it was recorded at 5.02 for the last single week of trading, and 7.07 for the last 200 days.
Avenue Therapeutics Inc. [ATXI]: An insightful look at the core fundamentals
Avenue Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
Avenue Therapeutics Inc. [ATXI]: Insider Ownership positions
There are presently around $0 million, or 3.10% of ATXI stock, in the hands of institutional investors. The top three institutional holders of ATXI stocks are: VANGUARD GROUP INC with ownership of 8,772, which is approximately -70.932% of the company’s market cap and around 53.54% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 8,294 shares of the stock with an approximate value of $60000.0 in ATXI stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $41000.0 in ATXI stock with ownership of nearly 0% of the company’s market capitalization.
7 institutional holders increased their position in Avenue Therapeutics Inc. [NASDAQ:ATXI] by around 14,799 shares. Additionally, 12 investors decreased positions by around 39,305 shares, while 3 investors held positions by with 9,128 shares. The mentioned changes placed institutional holdings at 44,976 shares, according to the latest SEC report filing. ATXI stock had 5 new institutional investments in for a total of 13,408 shares, while 4 institutional investors sold positions of 11,786 shares during the same period.